MacLennan, StevenWilliamson, Paula R.Bekema, Hendrika JCampbell, MarionRamsay, CraigN'Dow, JamesMacLennan, SaraVale, LukeLam, ThomasCOMPACTERS study group2018-05-032018-05-032017-11MacLennan, S, Williamson, P R, Bekema, H J, Campbell, M, Ramsay, C, N'Dow, J, MacLennan, S, Vale, L, Lam, T & COMPACTERS study group 2017, 'A core outcome set for localised prostate cancer effectiveness trials', BJU International, vol. 120, no. 5B, pp. E64-79. https://doi.org/10.1111/bju.138541464-4096ORCID: /0000-0002-2691-8421/work/61024728ORCID: /0000-0003-1405-6964/work/61511044ORCID: /0000-0003-4043-7349/work/128322849ORCID: /0000-0001-5386-4097/work/128323508ORCID: /0000-0001-5340-0081/work/162725379http://hdl.handle.net/2164/10420Acknowledgements The authors wish to thank the following: Heather Bagley and Linda Pennet for their advice and assistance regarding patient and public involvement in research; Janice Forsyth and Sarah Murdoch for their assistance with logistics before and during the consensus meeting; Melanie Harper-Jones and Duncan Appelbe for their support in designing and managing the online Delphi survey and data; Vikki Entwistle for her advice during the protocol development stage; and Jane Blazeby and Liz Gargon for providing advice on Delphi survey and consensus meeting methods. Finally, we would like to thank all patients and HCPs who took part in the interview study and Delphi survey. Funded by Cancer Research Aberdeen and North East Scotland (CRANES) Sonacare Inc Sophiris Biocorp Inc Trod Medical Takeda pharmaceutical / Millenium Astellas Pierre Fabre Sanofi Pasteur1691958engSDG 3 - Good Health and Well-beingcore outcome setlocalised prostate cancerclinical trialsconsensus processDelphi surveyconsensus group meetingR MedicineGeneral MedicineRJournal article10.1111/bju.138541205